Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 13-20, March 2008

Can FLT3 inhibitors overcome resistance in AML?

  • Winnie F. Tam, PhD
    • ,
  • D. Gary Gilliland, PhD, MD

      Affiliations

    • Corresponding Author InformationDepartment of Medicine, Brigham and Women's Hospital, 1 Blackfan Circle, Room 5.0210, Boston, MA 02115, USA. Tel.: +1 (617) 355 9092; Fax: +1 (617) 355 9093.

Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1521-6926(07)00093-X

doi:10.1016/j.beha.2007.11.003

Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 13-20, March 2008

Article Tools

* Image Usage & Resolution